DAX ®11.837,43+0,12%TecDAX ®1.904,78+0,43%Dow Jones20.832,39-0,02%NASDAQ 1005.343,57-0,07%

DGAP-Adhoc: aap Implantate AG: aap sells biomaterials business for EUR 36 million and becomes a pure player in trauma with innovative technologies

| Quelle: Dow Jones Newswire Web

DGAP-Ad-hoc: aap Implantate AG / Key word(s): Disposal/Change in Forecast
aap Implantate AG: aap sells biomaterials business for EUR 36 million and becomes a pure player in trauma with
innovative technologies

2016-03-22 / 02:21
Dissemination of an Ad hoc announcement according to § 15 WpHG.
The issuer is solely responsible for the content of this announcement.

Ad-hoc-Announcement according to § 15 WpHG

aap sells biomaterials business for EUR 36 million and becomes a pure player in trauma with innovative technologies

- Closing of the transaction will lead to adjustment of 2016 guidance; Postponement of publication of consolidated and
annual financial statements 2015 -

Berlin, 22 March 2016

aap Implantate AG ("aap") signed a notarized share purchase agreement today with a leading European private equity firm
for the sale of 100% of the company shares in its subsidiary aap Biomaterials GmbH, which has its registered office in
Dieburg. The purchase price is based on an assumed enterprise value of aap Biomaterials GmbH of EUR 36 million and will
be due for payment after closing of the transaction. The closing of the transaction is subject to the market standard
conditions precedent, which are to be met within the next three months. Upon closing of the transaction, the existing
profit and loss transfer agreement between aap and aap Biomaterials GmbH will be terminated.

The operation sold within the transaction (discontinued operation) consists of aap Biomaterials GmbH, which is
specialized in the development, production and marketing of bone cements, mixing systems and related accessories, and
aap's distribution business in this area. In 2015, the operation sold recorded sales based on preliminary figures
amounting to EUR 16.0 million.

The closing of the transaction will result in a positive one-time deconsolidation effect on the earnings level. The
company plans to use part of the proceeds to finance further growth and to distribute part of them to its shareholders.

The complete consolidated and annual financial statements as of 31 December 2015 of aap will be published by 29 April
2016 the latest. The reason for the delay in the publication is the sale of aap Biomaterials GmbH, which must already be
stated as a so-called discontinued operation in the consolidated financial statements for 2015. This leads to extensive
reporting requirements in the notes and the management report as well as in various presentations of results in the
consolidated financial statements.

Upon closing of the transaction, aap's previous sales and EBITDA forecast for the 2016 financial year will be no longer
valid. The company will publish a new and updated guidance for the current financial year after closing. In this
context, aap aims to announce also further details regarding the use of a part of the proceeds for the benefit of the

The closing of the transaction is the last step in the transformation of aap from a general medtech company to a pure
player in trauma.

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.:
++49/30/750 19 - 290; f.franke@aap.de

2016-03-22 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press
Media archive at www.dgap-medientreff.de and www.dgap.de

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg,
Hanover, Munich, Stuttgart

End of News DGAP News Service
447469 2016-03-22

(END) Dow Jones Newswires

March 21, 2016 21:21 ET (01:21 GMT)


FSE 1,34 -0,52%
EUR 11:16:20 -0,01

zum Kursportrait AdHoc-Meldungen & Insidertrades
Jetzt 1,00% p.a. Zinsen aufs Festgeld - für 12 Monate |Top Baufinanzierung bei der Degussa Bank |Das ATB Tagesgeldkonto - Transparenz für Ihr Geld
Bid & Ask Newsletter kostenlos lesen! |Jetzt Wünsche erfüllen mit dem PrivatKredit der Degussa Bank.
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter
Aktuelle Umfrageschliessen
Wie eine Supermarktkette verschwindet. Aus Kaisers wird Rewe. Was denken Sie darüber?
Jetzt abstimmen!
Alle Umfragen ansehen
Börse Stuttgart Anlegerclubschliessen

Attraktive Preise zu gewinnen!

Der Anlegerclub der Börse Stuttgart
verlost beim Gewinnspiel "Trade & Win"
regelmäßig attraktive Preise. Außerdem profitieren Mitglieder von lehrreichen Live-Webinaren, einem informativen Anlegermagazin und vielem mehr.

Jetzt kostenlos Mitglied werden